Back to Authors

Araújo, Raphael L. C.

0000-0002-7834-5944

Mayo Clinic

Carolinas Healthcare System

Citations 1

Novel Benchmarks for Robotic Whipple Surgery - A Global Multicenter Cohort Study
Pfister, Matthias , Chérif, Rim , Foroutani, Laleh , Iben-Khayat, Abdallah , Nunez, R, Takishita, Chie, Vigia, Emanuel , Boggi, Ugo , Lee, Jae Hoon , Martinie, J., Mejia, Alejandro , Pessaux, Patrick , Saint‐Marc, Olivier , Wakabayashi, Go, Clavien, Pierre-Alain, Li, Zhen , Abbassi, Fariba , Araújo, Raphael L. C. , Cherif, R, Giannone, Fabio , Nunez, R, Vivian, Elaina , Wakabayashi, Taiga , Alseidi, Adnan A. , Benedetto, Fabrizio Di , Brustia, Raffaele , Cheung, Tan To , Goh, Brian K P , Ielpo, Benedetto , Machado, Marcel Cerqueira César , Marques, Hugo P. , Nagakawa, Yuichi , Polanco, Patricio Marcelo

British Journal of Surgery | May 16, 2025 | Volume: 112 | Issue: Supplement_7 | Pages: No page available

10.1093/bjs/znaf092.036 Get It

Abstract Background Robotic Whipple holds the promise to overcome safety concerns associated with laparoscopy, paving the way for widespread implementation of minimal-invasive surgery in this complex procedure. However, randomized data comparing robot vs. open Whipple demonstrate more pancreas-specific complications and R1-resections in the robotic arm. Recent international consensus identified establishing benchmarks as critical to ensure safe adoption of the robot. Benchmarking is a validated quality improvement tool, enabling comparison of surgical performance. Aims The aim was to define benchmarks for outcome parameters in robotic Whipple. Methods We analyzed consecutive patients undergoing robotic Whipple from January 2020 until December 2023 in 11 centers across 4 continents, with a minimum one-year follow-up. Centers had to perform ≥15 cases/year and have mounted their learning curve. Benchmark criteria included benign or resectable malignant disease without neoadjuvant therapy, arterial resection, major co-morbidities, or significant previous abdominal surgery. Medians across centers represented benchmark cutoffs. Results Eleven centers performed 1’037 Whipple procedures, of which 603 (58%) were benchmark cases. One third (n=192) were pancreatic ductal adenocarcinoma (PDAC) patients. Key benchmarks at 6 months included ≤1.2% mortality, ≤24.2% major complications, and ≤ 8.7 points Comprehensive Complication Index®. Pancreas-specific cutoffs included ≤13.0% postoperative pancreatic fistula (POPF) B/C and ≤3.4% post-pancreatectomy hemorrhage B/C, with 100% R0-resection and ≥19 harvested lymph nodes in PDAC patients. One-year actuarial overall and recurrence-free survival was 87% and 77%. In the entire cohort POPF B/C occurred in 16% (n=195). Independent POPF predictors included duct diameter ≤4mm (OR 1.79 95%CI [1.27-2.55]), anticoagulation (OR 3.68 95%CI [2.14-6.24]), and indication other than PDAC (OR 3.17, 95%CI [2.13-4.85]). Conclusion This study establishes benchmarks for key outcomes in robotic Whipple, demonstrating oncologic adequacy and morbidity comparable to open surgery. Risk factors for POPF in open surgery also hold true in the robotic approach.